Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.
Ocular Therapeutix, Inc. reports news around ophthalmic drug development, commercial product activity and corporate governance for a Nasdaq-listed biopharmaceutical company using ELUTYX proprietary bioresorbable hydrogel formulation technology. Recurring updates focus on AXPAXLI, also known as OTX-TKI, an axitinib intravitreal hydrogel candidate for retinal disease, including wet age-related macular degeneration and diabetic retinal disease such as non-proliferative diabetic retinopathy.
Company announcements also cover DEXTENZA, an FDA-approved corticosteroid for ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, as well as OTX-TIC, a travoprost intracameral hydrogel program for open-angle glaucoma or ocular hypertension. Other recurring items include financial results, scientific and investor conference participation, clinical-study presentations and inducement equity grants under Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL) has announced its participation in major investor and scientific conferences in May 2025. The company's leadership team, including Executive Chairman Dr. Pravin Dugel, will present at the Citizens JMP Life Sciences Conference (May 7) and Bank of America Global Healthcare Conference (May 13).
The company will have significant presence at key scientific events including Eyecelerator, ARVO 2025, and Retina World Congress. Notable presentations will focus on their axitinib hydrogel (OTX-TKI) research for diabetic retinopathy and macular degeneration. Multiple studies will be presented, including results from the HELIOS trial and research on retinal leakage assessment.
Key executives participating include Chief Medical Officer Dr. Waheed, Chief Business Officer Saroj, and Chief Strategy Officer Dr. Nayak. The presentations will showcase Ocular's advances in novel drug delivery approaches for retinal conditions.
Ocular Therapeutix (NASDAQ: OCUL) announced it will release its first quarter 2025 financial results on Monday, May 5, 2025 at 7:00 AM Eastern Time. The biopharmaceutical company, focused on redefining the retina experience, stated it will not host a Q1 2025 conference call but plans to resume quarterly earnings calls starting with Q2 2025 results.
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for two new employees, including Thomas J. Cella, appointed as Executive Director of Payer Access. The awards, granted on April 7, 2025, include:
For Mr. Cella:
- Non-statutory stock option to purchase 26,000 shares
- Restricted stock unit award for 8,500 shares
For the non-executive employee:
- Non-statutory stock option to purchase 23,500 shares
- Restricted stock unit award for 7,700 shares
The stock options have a $6.30 per share exercise price and a ten-year term, vesting over four years. The restricted stock units vest over three years in equal annual installments, beginning April 7, 2026. These awards were granted under Ocular's 2019 Inducement Stock Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on retina treatments, has announced its participation in two major investor conferences this April. The first event is the 24th Annual Needham Virtual Healthcare Conference, where Dr. Pravin U. Dugel, Executive Chairman, President and CEO, will present on Monday, April 7, 2025, at 3:00 PM ET in a virtual format.
The second event is the Piper Sandler Spring Biopharma Symposium in Boston, MA, scheduled for Thursday, April 17, 2025, where the company will host one-on-one meetings with investors. Interested parties can access a live webcast of the Needham presentation through the Events and Presentations section of Ocular's Investor Relations webpage.
Ocular Therapeutix (NASDAQ: OCUL) has announced inducement awards for a new employee under its 2019 Inducement Stock Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4). The grants, effective March 3, 2025, include:
- A non-statutory stock option to purchase 48,000 shares at market price
- A restricted stock unit (RSU) award for 15,500 shares
The stock option has a 10-year term with a 4-year vesting schedule: 25% vesting on March 3, 2026, and the remainder monthly over three years. The RSU award vests over three years in equal annual installments, starting March 3, 2026. Both awards require continued employment with Ocular through vesting dates.
Ocular Therapeutix (NASDAQ: OCUL) reported Q4 and full year 2024 results, highlighting significant progress in their AXPAXLI registrational program for wet AMD treatment. The company announced FDA approval for re-dosing at Weeks 52 and 76 in the SOL-1 trial, with primary endpoint data expected in Q1 2026.
Key financial highlights include:
- Cash position of $392.1M as of December 31, 2024, funding operations into 2028
- Q4 2024 total revenue of $17.1M, up 15.4% year-over-year
- Full year 2024 revenue of $63.7M, a 9.0% increase from 2023
- Q4 2024 net loss of $(48.4M), or $(0.29) per share
The company reduced SOL-R trial size to 555 subjects from 825, potentially accelerating registration timelines. FDA feedback on AXPAXLI in NPDR and DME is expected in 1H 2025.
Ocular Therapeutix (NASDAQ: OCUL), a biopharmaceutical company focused on redefining the retina experience, has announced its participation in two major investor conferences in March 2025.
The company will first attend the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4, 2025, where Executive Chairman, President and CEO Pravin U. Dugel, MD will participate in a fireside chat at 11:50 AM ET.
Following this, Ocular will join the Leerink Partners Global Healthcare Conference 2025 in Miami Beach on Monday, March 10, 2025, with another fireside chat scheduled for 10:00 AM ET, also featuring Dr. Dugel.
Investors can access live webcasts of both presentations through the Events and Presentations section on the Investor Relations page of the Ocular Therapeutix website.
Ocular Therapeutix (NASDAQ: OCUL) has announced it will host a conference call and webcast on Monday, March 3, 2025, at 8:00 AM ET to discuss its fourth quarter and full year 2024 financial results and recent business developments. The company, which focuses on redefining the retina experience, will provide access to the event through both U.S. (1-877-407-9039) and International (1-201-689-8470) dial-in numbers. The webcast will be available live and archived on the company's Investor Relations page for at least 30 days following the presentation.
Ocular Therapeutix (NASDAQ: OCUL) has announced multiple presentations scheduled for the Angiogenesis, Exudation, and Degeneration 2025 virtual meeting on February 8, 2025. The presentations will focus on their key product OTX-TKI, featuring three distinct sessions:
1. Dr. Carl J. Danzig will present on OTX-TKI's progression from Phase 1 to Phase 3, discussing the SOL-1 and SOL-R trials for neovascular AMD at 2:30 PM ET.
2. Dr. Mark R. Barakat will share Phase 1 results of the intravitreal axitinib implant (OTX-TKI) for treating non-proliferative diabetic retinopathy at 5:20 PM ET.
3. Dr. Justis P. Ehlers will present volumetric macular fluid analysis findings from the HELIOS Clinical Trial at 5:25 PM ET, examining the impact of a single axitinib intravitreal implant in diabetic retinopathy treatment.